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Abstract
Introduction
The primary receptor for SARS-CoV-2 infection, angiotensin-converting enzyme-2 (ACE-2), is expressed in
the gastrointestinal tract and liver parenchyma. The involvement of the gastrointestinal tract with severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has remained unclear. The following
study retrospectively reviews gastrointestinal symptoms and liver function tests at the time of hospital
admission to identify patient outcomes including prolonged hospital stay, the requirement for intensive
care, and all-cause in-hospital 30-day mortality.
Methods
A retrospective review of patient charts at the Woodhull Medical and Mental Health Center (WMC) was
conducted at the time of hospital admission, using a pre-determined selection criterion. All adult patients,
both inpatient and outpatient, were included from March 2020 till May 2020. A 95% confidence interval was
used to estimate the odds ratio (OR) for patient outcomes.
Results
Of the 520 patients, gastrointestinal symptoms including nausea (OR = 0.375, p = 0.015), and nausea and
vomiting in combination (OR = 0.400, p = 0.016) had an inverse protective relationship with all-cause in-
hospital 30-day mortality among COVID-19 patients. Gastrointestinal symptoms including diarrhea (OR =
1.008, p < 0.001), and nausea and vomiting (OR = 1.291, p = 0.043) had a mild impact on the length of
hospital stay.
Conclusion
Elevated liver transaminases including alanine transaminase (ALT) and aspartate transaminase (AST) at the
time of hospital admission can predict critical care requirement and all-cause 30-day hospital mortality in
patients with COVID-19 infection. Presence of gastrointestinal symptoms is associated with worsened
outcomes.
Categories: Gastroenterology, Infectious Disease, Epidemiology/Public Health
Keywords: gastrointestinal, symptoms, liver, transaminases, prognosis, covid-19
Introduction
Ever since coronavirus disease 2019 (COVID-19) was declared a global health emergency, it has caused over
2.48 million deaths as of February 23, 2021. The respiratory tract manifestations have been commonly
observed with fever and cough being reported most frequently [1]. However, recent studies have
demonstrated that the gastrointestinal tract and liver may also serve as target organs for severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) [2]. Such findings are corroborated on the basis that the
angiotensin-converting enzyme 2 (ACE-2), the primary receptor for SARS-CoV-2, is presented in the
gastrointestinal tract and liver parenchyma [3]. While the impact of SARS-CoV-2 on the gastrointestinal
tract and liver remains unclear, COVID-19 patients presenting with digestive symptoms and deranged liver
function tests (LFTs) may have a worse prognosis [4].
We conducted a retrospective review of patient data to correlate the presence of digestive symptoms and
derangement of LFTs with the duration of hospital stay, the requirement for intensive care, and 30-day
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mortality of COVID-19 patients admitted to Woodhull Medical Center from March 2020 till May 2020.
Materials And Methods
Study design and population
A retrospective review of patient charts at the Woodhull Medical and Mental Health Center (WMC) was
conducted. All patients aged 18 years and above were included with no restriction to gender, race, or
ethnicity. Only pre-existing data, both inpatient and outpatient, was included from March 2020 till May
2020. Data were obtained from patient records, both electronic and paper records, from the WMC. Specific
data were reviewed including patient demographics, gastrointestinal symptomatology, laboratory values at
the time of hospital admission, progress notes, and procedure notes.
Data collection
Privacy and security were maintained by password protecting identifiable data and minimizing access to
identifiable data. All datasheets were password protected and all paper records were stored in a keyed file
drawer in a locked office. Following the acquisition of information, surrogate numbers were given to identify
patients for data analysis, and a key was kept in a separate password-protected excel sheet to be searched
until after completion of the study at which time it was deleted. The principal and co-investigators reviewed
the charts and were the only members to have access to the subjects' data.
Statistical analysis
The statistical analysis was conducted to assess the role of various factors in patient outcomes. The
frequency of gastrointestinal symptoms and elevated LFTs were specified. Only the parameters obtained at
the time of hospital admission were used to conduct the statistical analysis. The primary outcome was to
determine the 30-day mortality, ICU admission, and hospital stay following COVID-19 diagnosis for
enrolled patients. The results of the multivariate analysis were presented in terms of the odds ratio (OR). A
difference with a two-sided α < 0.05 was considered statistically significant. The data analysis was
conducted on Statistical Package for Social Sciences (SPSS) version 26.0 (IBM Corp., Armonk, NY).
Results
A total of 520 patients were reviewed retrospectively who were polymerase chain reactive (PCR) positive for
COVID-19. Among these, 60 patients had only nausea, 37 patients had only vomiting, and 63 patients with
nausea and vomiting. Only 64 patients had diarrhea as their only gastrointestinal manifestation. A total of














Patients with any combination of one or
more of the 3
n 520 60 37 63 64 105
TABLE 1: Gastrointestinal symptomatology of participants
Of the 520 patients, 344 patients had deranged international normalized ratio (INR) (Table 2). Nearly all of
the patients (n = 488) had elevated aspartate transaminase (AST) and alanine transaminase (ALT) in
combination (Table 2).
 All patients Patients with deranged INR Patients with elevated AST and ALT Patients with decreased albumin (<3.5)
n 520 344 488 481
TABLE 2: Laboratory findings of participants
INR: International normalized ratio; AST: Aspartate transaminase; ALT: Alanine transaminase.
Patients presenting with nausea (OR = 0.375, p = 0.015), as well as nausea and vomiting in combination (OR
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= 0.400, p = 0.016), had a significant 30-day mortality rate (Table 3). Elevation of ALT (OR = 1.558, p = 0.038),
AST (OR = 2.743, p < 0.001), and in combination (OR = 2.593, p < 0.001) had a significant impact on the 30-
day mortality rate (Table 3).
        
Symptoms 30-day mortality rate Odds ratio (OR)
95% Confidence Interval
P-value
 Lower Upper  
Nausea 5.8% 0.375 0.166 0.849 0.015
Vomiting 4.2% 0.471 0.179 1.239 0.160
Diarrhea 9.0% 0.630 0.325 1.22 0.222
Nausea and Vomiting 6.7% 0.400 0.185 0.864 0.016
Elevated INR (>1.5) 17.3% 1.824 0.941 3.536 0.072
Elevated Transaminases (AST > 40 and ALT > 45) 78.2% 2.593 1.635 4.111 0.000
AST > 40 33.6% 2.743 1.739 4.327 0.000
ALT > 45 32.9% 1.558 1.023 2.372 0.038
Low Albumin (<3.5) 43.9% 1.120 0.749 1.676 0.580
TABLE 3: Predictors of 30-day mortality rate
INR: International normalized ratio; AST: Aspartate transaminase; ALT: Alanine transaminase.
Diarrhea as a gastrointestinal (GI) manifestation was a significant contributor to prolonged hospital stay
lasting ≥ 10 days (OR = 1.008, p < 0.001) (Table 4). Nausea and vomiting were also associated with prolonged
hospital stay lasting ≥10 days (OR = 1.291, p = 0.043) (Table 4).






<10 days ≥10 days Lower Upper
Nausea 11.0% 13.9% 1.307 0.760 2.249 0.332
Vomiting 7.2% 8.0% 1.12 0.569 2.204 0.742
Diarrhea 12.3% 12.4% 1.008 0.591 1.717 0.000
Nausea and Vomiting 12.0% 15.0% 1.291 0.764 2.182 0.043
Elevated INR (>1.5) 13.1% 11.1% 0.827 0.431 1.586 0.567
Elevated Transaminases (AST > 40 and ALT > 45) 64.3% 62.2% 0.915 0.633 1.323 0.637
AST > 40 only 61.5% 61.2% 0.989 0.686 1.424 0.952
ALT > 45 only 30.2% 29.2% 0.951 0.644 1.403 0.799
Low Albumin (<3.5) 39.7% 45.6% 1.275 0.887 1.832 0.188
TABLE 4: Predictor of prolonged hospital stay (≥10 days)
INR: International normalized ratio; AST: Aspartate transaminase; ALT: Alanine transaminase.
Patients with elevated ALT only (OR = 1.594, p = 0.019), AST only (OR = 2.149, p < 0.001), and both ALT and
AST (OR = 2.022, p < 0.001) were all significant predictors of intensive care unit (ICU)/progressive care unit
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(PCU) care (Table 5). Symptoms including nausea, vomiting, and diarrhea did not lead to increased odds of






Admission rates Lower Upper
Nausea 10.1% 0.707 0.396 1.262 0.239
Vomiting 5.9% 0.712 0.34 1.491 0.366
Diarrhea 10.9% 0.827 0.475 1.442 0.504
Nausea and Vomiting 14.3% 0.761 0.435 1.331 0.337
Elevated INR (>1.5) 13.6% 1.206 0.636 2.286 0.566
Elevated Transaminases (AST > 40 and ALT > 45) 72.6% 2.022 1.37 2.986 0.000
AST > 40 only 71.6% 2.149 1.461 3.161 0.000
ALT > 45 only 36.0% 1.594 1.078 2.357 0.019
Low Albumin (<3.5) 46.2% 1.318 0.913 1.904 0.140
TABLE 5: Predictor for requirement of ICU/PCU care
ICU: Intensive care unit; PCU: Progressive care unit; INR: International normalized ratio; AST: Aspartate transaminase; ALT: Alanine transaminase.
Discussion
We conducted a retrospective review of patients admitted with gastrointestinal manifestations following
COVID-19 infection. Gastrointestinal involvement was assessed by reviewing gastrointestinal symptoms,
and liver function test abnormalities. Our findings demonstrate longer hospital stays (≥10 days) among
patients manifesting with gastrointestinal symptoms including diarrhea, and a combination of nausea and
vomiting. However, we also found that the presence of gastrointestinal symptoms was suggestive of a
reduced 30-day mortality rate. Hepatic predictors including elevated ALT and AST had a strong association
with the 30-day mortality rate and critical care requirement. Low albumin and elevated INR did not have any
impact on the prognosis of patients with COVID-19 infection in our cohort.
The underlying mechanism for gastrointestinal involvement in COVID-19 is similar to that of respiratory
and due to the attachment of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE-2)
receptor in the digestive system, particularly the proximal large intestine [5]. Previous studies have reported
data on the involvement of the gastrointestinal tract and liver [6,7]. Mao et al. identified a pooled prevalence
of 15% for gastrointestinal symptoms in COVID-19 of whom 10% did not have respiratory involvement [2].
Gastrointestinal symptoms have been observed among patients with COVID-19 infection in literature with
discrepancies in their predictive prognostic potential [8,9]. In our cohort, GI symptoms had an inverse
protective relationship with the 30-day mortality rate. However, our analysis demonstrates a significant
impact of diarrhea, and nausea, and vomiting in combination on the duration of hospital stay. Additionally,
the gastrointestinal manifestations had no contribution to the patients' requirements for critical care
admissions. With conflicting reports of the impact of gastrointestinal symptoms on COVID-19 infection
outcomes, our analysis also demonstrates both their positive and negative prognostic potential.
Our findings suggest that, as the liver involvement is suggested through ALT and AST elevation, patients
have worse 30-day mortality rates and require critical care with the difference proving significant. Reports
of liver injury have been suggested earlier including elevated transferases and INR, and decreased albumin
levels, among patients with COVID-19 [10,11]. While our findings did not identify low serum albumin as a
prognostic marker as reported by Huang et al. [12], elevated transaminases were suggestive of worse
outcomes in our cohort of COVID-19-infected patients. Our findings from recent literature show that
elevated AST and/or ALT are associated with increased mortality rates.
Strengths and limitations
The main strengths of our study include a large sample size (n = 520) and the longitudinal study design in
New York City, a prominent epicenter of the COVID-19 pandemic. The lab parameters and gastrointestinal
manifestations were assessed on the day of admission. To the best of our knowledge, this is the first study
that observes both liver function tests as well as gastrointestinal symptoms on the day of hospital admission
to assess their prognostic potential.
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The main limitations of our study include the lack of categorization of the existing burden of chronic liver
disease and the use of medications that might be hepatotoxic. As the gastrointestinal symptoms and liver
injury markers were assessed at the time of hospital admission, patients with pre-existing liver injury may
have been included. No testing was conducted to assess the hepatitis B and C status of these patients.
Similarly, the baseline comorbidities and other health parameters, i.e. presence of respiratory symptoms,
were not controlled for in the analysis.
Recommendations
Gastrointestinal manifestations of COVID-19 may manifest early in the course of the disease, possibly
occurring in isolation. Management of patients with COVID-19 infection should also contain the potential
prognostic impact of liver markers and gastrointestinal symptoms. With a great interest in the prognostic
capacity of gastrointestinal symptoms and liver involvement, this study identifies a worse prognosis among
COVID-19 patients. While the main target organ of COVID-19 infection remains the respiratory system, the
impact of gastrointestinal involvement may not be undermined as has been observed in the literature [13-
15].
Conclusions
Elevated liver transaminases including ALT and AST at the time of hospital admission can predict critical
care requirement and all-cause 30-day hospital mortality in patients with COVID-19 infection. Presence of
gastrointestinal symptoms is associated with worsened outcomes.
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